Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Dow
McKinsey
Chubb
McKesson
US Department of Justice
Daiichi Sankyo
Fuji
QuintilesIMS

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,962,680

« Back to Dashboard

Which drugs does patent 8,962,680 protect, and when does it expire?

Patent 8,962,680 protects MYTESI and is included in one NDA.

This patent has nineteen patent family members in seventeen countries.
Summary for Patent: 8,962,680
Title:Methods and compositions for treating HIV-associated diarrhea
Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Inventor(s): Forbes; William (Raleigh, NC), Bortey; Enoch (Chapel Hill, NC), King; Steven (Moss Beach, CA), Chaturvedi; Pravin (Andover, MA)
Assignee: Salix Pharmaceuticals, Ltd. (Raleigh, NC) Napo Pharmaceuticals, Inc. (San Francisco, CA)
Application Number:13/285,397
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,962,680

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,962,680

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,585,868 Methods and compositions for treating HIV-associated diarrhea ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
US Department of Justice
Cantor Fitzgerald
Queensland Health
Farmers Insurance
US Army
Chubb
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.